tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2022 Aug 1;2101334.
doi: 10.1080/21645515.2022.2101334. Online ahead of print.
SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case
Olgo A Mukhina[SUP] 1 [/SUP], Daria S Fomina[SUP] 1 2 [/SUP], Vasiliy V Parshin[SUP] 1 [/SUP], Vladimir A Gushchin[SUP] 3 4 [/SUP], Inna V Dolzhikova[SUP] 3 [/SUP], Alexey M Shchetinin[SUP] 3 [/SUP], Dmitriy M Chudakov[SUP] 5 6 [/SUP], Evgeniia Alekseeva[SUP] 5 [/SUP], Dmitriy Korostin[SUP] 6 [/SUP], Georgii A Bazykin[SUP] 5 7 [/SUP], Galya Klink[SUP] 7 [/SUP], Denis Yu Logunov[SUP] 3 [/SUP], Maryana A Lysenko[SUP] 1 6 [/SUP]
Affiliations
Abstract
The article highlights the course of long-term SARS-CoV-2 infection in a patient with a secondary immunodeficiency developed with B-cell-depleting therapy of the underlying disease. Analysis of the intrapatient virus evolution revealed an inpatient S:G75A mutation that alters the 72GTNGTKR78 motif of the S-protein, with a possible role in binding to alternative cellular receptors. Therapy with a ready-made COVID-19-globulin preparation (native human immunoglobulin G (IgG) derived from the plasma of convalescent COVID-19-patients) resulted in rapid improvement of the patient's condition, fast, and stable elimination of the virus, and passive immunization of the patient for at least 30 days. The results suggest the use of products containing neutralizing antibodies opens new prospects for treatment algorithms for patients with persistent coronavirus infection, as well as for passive immunization schemes for patients with a presumably reduced specific response to vaccination.
Keywords: B-cell depletion; COVID-19; Immunodeficiency; Rituximab; SARS-CoV-2; convalescent plasma; coronavirus evolution; human immunoglobulin; normal human intravenous immunoglobulin.
. 2022 Aug 1;2101334.
doi: 10.1080/21645515.2022.2101334. Online ahead of print.
SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case
Olgo A Mukhina[SUP] 1 [/SUP], Daria S Fomina[SUP] 1 2 [/SUP], Vasiliy V Parshin[SUP] 1 [/SUP], Vladimir A Gushchin[SUP] 3 4 [/SUP], Inna V Dolzhikova[SUP] 3 [/SUP], Alexey M Shchetinin[SUP] 3 [/SUP], Dmitriy M Chudakov[SUP] 5 6 [/SUP], Evgeniia Alekseeva[SUP] 5 [/SUP], Dmitriy Korostin[SUP] 6 [/SUP], Georgii A Bazykin[SUP] 5 7 [/SUP], Galya Klink[SUP] 7 [/SUP], Denis Yu Logunov[SUP] 3 [/SUP], Maryana A Lysenko[SUP] 1 6 [/SUP]
Affiliations
- PMID: 35914217
- DOI: 10.1080/21645515.2022.2101334
Abstract
The article highlights the course of long-term SARS-CoV-2 infection in a patient with a secondary immunodeficiency developed with B-cell-depleting therapy of the underlying disease. Analysis of the intrapatient virus evolution revealed an inpatient S:G75A mutation that alters the 72GTNGTKR78 motif of the S-protein, with a possible role in binding to alternative cellular receptors. Therapy with a ready-made COVID-19-globulin preparation (native human immunoglobulin G (IgG) derived from the plasma of convalescent COVID-19-patients) resulted in rapid improvement of the patient's condition, fast, and stable elimination of the virus, and passive immunization of the patient for at least 30 days. The results suggest the use of products containing neutralizing antibodies opens new prospects for treatment algorithms for patients with persistent coronavirus infection, as well as for passive immunization schemes for patients with a presumably reduced specific response to vaccination.
Keywords: B-cell depletion; COVID-19; Immunodeficiency; Rituximab; SARS-CoV-2; convalescent plasma; coronavirus evolution; human immunoglobulin; normal human intravenous immunoglobulin.